Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study
2019 · Journal of Clinical Oncology · 679 citations
https://doi.org/10.1200/jco.19.01638
J
Jeffrey C. Goh
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
129
Papers
9.9K
Citations
28
h-index
46
i10-index
Jeffrey C. Goh is an academic researcher from Queensland University of Technology. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Prostate Cancer Treatment and Research & Renal cell carcinoma treatment. The author has an h-index of 28, co-authored 110 publications.
ORCID: 0000-0003-3103-146XPapers by this author
worksLenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study
2023 · The Lancet Oncology · 149 citations
https://doi.org/10.1016/s1470-2045(23)00049-9
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study
2024 · Journal of Clinical Oncology · 137 citations
https://doi.org/10.1200/jco.23.01569
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study
2024 · Journal of Clinical Oncology · 137 citations
https://doi.org/10.1200/jco.23.01569
Clinical impact of Prostate-Specific Membrane Antigen Positron Emission Tomography (PET) on intensification or deintensification of advanced renal cell carcinoma management
2023 · European Journal of Nuclear Medicine and Molecular Imaging · 7 citations
https://doi.org/10.1007/s00259-023-06380-4
716MO Efficacy and safety of sacituzumab tirumotecan (sac-TMT) plus pembrolizumab in patients with recurrent or metastatic cervical cancer
2024 · Annals of Oncology · 5 citations
https://doi.org/10.1016/j.annonc.2024.08.778
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat